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Abstract
 
Glucocorticoids (GCs) affect peripheral immune responses by inhibiting T cell immunity at
several stages of the activation cascade, causing impaired cytokine production and effector
function. The recent demonstration that the thymic epithelium and possibly thymocytes them-
selves produce steroids suggests that endogenous GCs also play a role in the control of T cell
development. As both peripheral responsiveness and thymic differentiation appear to be regu-
lated by the quantity and quality of intracellular signals issued by antigen–major histocompati-
bility complex-engaged T cell receptor (TCR) complexes, we investigated the effects of GCs
on the signaling properties of T cells stimulated by anti-CD3 monoclonal antibodies or agonist
peptides. We demonstrate in this work that dexamethasone, a synthetic GC, inhibits the early
signaling events initiated upon TCR ligation, such as tyrosine phosphorylation of several
TCR-associated substrates including the 
 
z
 
 chain, the ZAP70 kinase, and the transmembrane
adapter molecule linker for activation of T cells. Hypophosphorylation was not a consequence
of reduced kinase activity of src protein tyrosine kinases, but was correlated with an altered-
membrane compartmentalization of these molecules. These observations indicate that in addi-
tion to their well-described ability to interfere with the transcription of molecules involved in
peripheral responses, GCs inhibit T cell activation by affecting the early phosphorylating events
induced after TCR ligation.
Key words: T lymphocyte • signal transduction • tyrosine kinases • membrane rafts • 
glycosphingolipid-enriched microdomains
 
Introduction
 
T cells undergo a complex and ordered program of pheno-
typic changes during both differentiation in the thymus
(positive versus negative selection) and after Ag encounter
in the periphery (helper subset differentiation, choice be-
tween activation and unresponsiveness, or apoptosis). Each
of these developmental transitions appears to be regulated
by the quantity and the quality of intracellular signals issued
by Ag–MHC-engaged TCR complexes (1).
 
Multiple models have been proposed to explain how a
single receptor can regulate opposing developmental deci-
sions. A currently favored model postulates that the
“strength” of TCR signaling plays a crucial role in T cell
development and differentiation (2). Indeed, numerous
studies have suggested that the TCR does not act as a sim-
ple on/off switch, but rather is able to translate subtle
changes in its ligand into unique signaling events leading to
different phenotypic outcomes (3). This signaling flexibil-
ity was first evidenced from the structural and functional
analysis of immunogenic peptide analogues lacking the
ability to stimulate some or all T cell effector activities
(partial agonists) (4–6). Compared with their immuno-
genic counterparts (which induce activation of peripheral
cells and cause negative selection in the thymus), these
variant TCR ligands induce distinct biological responses
such as T cell anergy in the periphery or positive selection
of developing thymocytes (7–10). Similarly, several studies
have shown that altering the strength of TCR stimulation
can influence the Th1–Th2 differentiation program of na-
ive T cells (11–14).
The precise mechanism by which the strength of TCR
signaling is translated into distinct developmental responses
 
Address correspondence to Oberdan Leo, Laboratoire de Physiologie An-
imale, Université Libre de Bruxelles, Rue des Prof. Jeener et Brachet 12,
B-6041 Gosselies, Belgium. Phone: 32-2650-9877; Fax: 32-2650-9860;
E-mail: oleo@dbm.ulb.ac.be 
804
 
Dexamethasone Inhibits TCR Signaling
 
is presently unknown. Recently, studies performed on ma-
ture T cells stimulated by variant TCR ligands have related
unique functional responses to a novel pattern of early
TCR-associated tyrosine phosphorylations. Stimulation of
naive T cells with a strong agonist peptide induces a full
spectrum of signaling events, including saturated phos-
phorylation of the TCR-associated 
 
z
 
 chain, the adaptor
molecule linker for activation of T cells (LAT),
 
1
 
 and the 
 
syk
 
kinase ZAP70, leading to sustained mobilization of intra-
cellular calcium and cytokine gene transcription. Stimula-
tion of cells with a low-avidity ligand is followed by an in-
complete phosphorylation program, characterized by the
predominance of the p21 phosphorylated form of the
TCR-associated 
 
z
 
 chain and the lack of phosphorylation of
ZAP70 (15–17). However, studies performed with devel-
oping thymocytes suggest that weak TCR ligands known
to induce positive selection do not necessarily induce a
unique phosphorylation pattern in these cells (qualitatively
different), but rather a gradient of phosphorylation events
(quantitatively different; reference 9). In either event, these
studies suggest that the level of phosphorylation of the re-
ceptor-associated immunoreceptor tyrosine-based activa-
tion motifs (ITAMs) reflects the intensity of the early sig-
nals derived by the TCR and may therefore serve as a first
level of regulation for determining signaling thresholds (1).
In most models studied to date, the nature of the signals
issued by the TCR and the resulting functional response
appears to be determined by the overall avidity of the
APC–T cell interaction, which is influenced by the affinity
of the Ag–MHC ligand for the TCR (18, 19), the extent of
receptor–coreceptor aggregation, and the nature of acces-
sory signals provided by the APCs (2, 20). However, nu-
merous studies have shown that immune responses in vivo
are not simply controlled by Ag recognition and cell–cell
interactions between lymphoid cells, but are also sensitive
to the endocrine milieu. Glucocorticoids (GCs) are well
known immunoregulatory agents widely used for the treat-
ment of autoimmune and allergic diseases and to prevent or
delay graft rejection (21). GCs are thought to exert their
antiinflammatory effect by inhibiting (directly or via inter-
action with other transcription factors) the transcription of
molecules (including cytokines) involved in peripheral im-
mune responses (22). Recently GCs have been shown to
regulate cell fate decisions both in the thymus and in the
periphery (23, 24), suggesting that they may affect TCR
signaling in a more complex manner than previously antic-
ipated. The observation that GCs regulate developmental
steps known to be sensitive to the strength of signals deliv-
ered to the TCR prompted us to study the mechanisms by
which dexamethasone (DEX), a GC analogue, inhibits T
 
cell activation. We demonstrate in this report that GCs af-
fect the signaling properties of the TCR by inhibiting the
early phosphorylating events induced after TCR ligation,
possibly through altered membrane compartmentalization
of several key enzymes and substrates. These observations
indicate that the nature of membrane-proximal signals de-
livered by the TCR is not only determined by the ligand
structure and avidity, but is also sensitive to the hormonal
environment, and suggest therefore a novel mechanism by
which steroids may regulate T cell differentiation and re-
sponsiveness.
 
Materials and Methods
 
Mice.
 
Balb/c mice, 6–8 wk old, were purchased from
Charles River Laboratories. Mice transgenic for the 
 
ab
 
 TCR,
from the F5 cytotoxic T cell clone, were generated as described
previously (25). These mice were crossed onto 
 
b
 
2-microglobulin
(
 
b
 
2m)-negative and recombination activating gene (Rag)-1–neg-
ative backgrounds and are referred to as F5 
 
b
 
2m
 
2
 
/
 
2
 
Rag1
 
2
 
/
 
2
 
.
 
Cell Culture, Reagents, and Abs.
 
The pigeon cytochrome c/IE
 
k
 
-
specific 3B4.15 murine hybridoma cell line was described
elsewhere (26). The thymic epithelial cell line YO1 (H-2b) was
generated as described previously (27). DEX (soluble in ethanol),
cycloheximide, saponin, and methyl-
 
b
 
-cyclodextrin were pur-
chased from Sigma-Aldrich. RU486 was obtained from Roussel
UCLAF. Cells were cultured in RPMI 1640 (Life Technologies)
supplemented with 5% FCS, nonessentials amino acids, 2 mM
 
L
 
-glutamine, penicillin-streptomycin, and 5
 
 3 
 
10
 
2
 
5
 
 M 
 
b
 
-mer-
captoethanol. Abs used in this study were specific for the follow-
ing markers: CD3
 
e
 
 (hamster mAb 145-2C11, American Type
Culture Collection; and mouse mAb 7D6, reference 28); CD3
 
z
 
(hamster mAb H146-968; provided by Dr. R. Kubo, National
Jewish Medical Center, Denver, CO); CD4 (rat mAb GK1.5;
American Type Culture Collection); TCR-
 
b
 
 (hamster mAb
H57-95; provided by Dr. R. Kubo); ZAP70 (rabbit serum 1222;
provided by Dr. A. Weiss, University of California at San Fran-
cisco, San Francisco, CA); LAT (rabbit serum 3023; provided by
Dr. L. Samelson, National Institutes of Health, Bethesda, MD);
Lck (mouse mAb; Santa Cruz Biotechnology, Inc.); Fyn (rabbit
serum; Santa Cruz Biotechnology, Inc.); CD90.1 (mouse mAb
OX7; provided by D.P. Draper, Academy of Sciences of the
Czech Republic, Prague, Czech Republic); phospholipase C
(PLC)
 
g
 
1 (rabbit serum; Santa Cruz Biotechnology, Inc.); phos-
photyrosine (mouse mAb 4G10; Upstate Biotechnology); CD45
(rat mAb M1/9.3.4.HL.2; American Type Culture Collection);
and CD90 (mouse mAb HO-13.4; American Type Culture Col-
lection). When indicated, Abs from ascitic fluids grown in nude
mice were purified by anion exchange chromatography (mono
Q; Amersham Pharmacia Biotech). F5 
 
b
 
2m
 
2
 
/
 
2
 
Rag1
 
2
 
/
 
2
 
 thy-
mocytes were stimulated with the following peptides: NP68
(from the nucleoprotein of influenza virus A/NT/60/68
[NP366–374]) and the control peptide glycosaminoglycan
(GAG) (from the GAG protein of the SF2 strain of HIV [390–
398]). They were both synthesized on a peptide synthesizer
(model 430A; Applied Biosystems).
 
Cell Stimulation, Immunoprecipitations, and Western Blot Analy-
ses.
 
Thymocytes and T cell hybridomas were cultured for 16 h
at 37
 
8
 
C in DEX or solvent (ethanol)-supplemented media, pel-
leted, and resuspended at 4 
 
3 
 
10
 
7
 
–10
 
8
 
 cells/ml in complete me-
dia. Cells were incubated for 5 min with anti-CD3 mAbs (clone
7D6, 10 
 
m
 
g/ml) and then cross-linked with rabbit anti–mouse Ig
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2m, 
 
b
 
2-microglobulin; DEX, dexa-
methasone; GAG, glycosaminoglycan; GC, glucocorticoid; GEM, glyco-
lipid-enriched membrane microdomain; GPI, glycosyl phosphatidylino-
sitol; HRP, horseradish peroxidase; ITAM, immunoreceptor tyrosine-based
activation motif; LAT, linker for activation of T cells; MES, morpholino-
ethane sulfonic acid; PLC, phospholipase C; PTK, protein tyrosine ki-
nase; Rag, recombination activating gene. 
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(20 
 
m
 
l serum/ml) for 90 s at 37
 
8
 
C. F5 
 
b
 
2m
 
2
 
/
 
2
 
Rag1
 
2
 
/
 
2
 
 (5 
 
3
 
 10
 
7
 
)
thymocytes were centrifuged briefly onto a monolayer of YO1
cells that were preincubated with the peptides for 2 h at 37
 
8
 
C.
After 5 min, thymocytes were removed and rapidly sedimented.
Cells were lysed in ice-cold 1% Brij97 lysis buffer (200 mM boric
acid, 150 mM NaCl, pH 8.0) containing 5 mM EDTA, 2 mM
sodium orthovanadate, 1 mM PMSF, 5 mM sodium fluoride, and
1 U/ml aprotinin). After clarification (13,000 rpm for 15 min),
cell lysates were subjected to immunoprecipitation with the indi-
cated Abs. Immunoprecipitations were performed using mAbs di-
rectly coupled to CNBr-activated Sepharose beads (Amersham
Pharmacia Biotech) or using polyclonal rabbit Abs and protein
A/G–Sepharose beads (Santa Cruz Biotechnology, Inc.). Note
that TCR complex–associated structures were immunoprecipi-
tated using the 145-2C11 anti-CD3
 
e
 
 mAb. The 7D6 anti-CD3
mAb used for TCR cross-linking does not compete with the
145-2C11 mAb for binding to the TCR complex (28), enabling
145-2C11–coupled beads to immunoprecipitate all TCR struc-
tures. Immunoprecipitates were resolved on SDS-PAGE (14%
gels; Novex) under reducing conditions. Secondary reagents in-
cluded horseradish peroxidase (HRP)-coupled protein A (Sigma-
Aldrich), HRP-sheep anti–mouse IgG (SAM; Abcam), and
HRP-goat anti–rat IgG (GAR; Southern Biotechnology Associ-
ates, Inc.). Western blotting and visualization of proteins by en-
hanced chemiluminescence (ECL; Amersham Pharmacia Bio-
tech) were performed as described previously (26). Densitometric
analysis was performed with the Molecular Analyst
 
®
 
 software
(Bio-Rad Laboratories).
 
Subcellular Fractionation.
 
Membrane and cytosol fractions
were obtained as follows. Cells (4 
 
3
 
 10
 
7
 
) were pelleted and sus-
pended at 10
 
8
 
 cells/ml in ice-cold lysis buffer containing 50 mM
Tris, 5 mM EDTA, and a complete, EDTA-free protease inhibi-
tor cocktail (Roche Biochemicals). The lysate was homogenized
and centrifuged at 1,600 rpm for 2 min at 4
 
8
 
C to remove non-
lysed cells and nuclei. The supernatant was ultracentrifuged at
22,000 rpm for 15 min at 4
 
8
 
C in an AH650 Sorvall rotor. The
supernatant was collected as the cytosol preparation (10
 
8
 
 cell
equivalent/ml). The pellet was washed, resuspended at 2 
 
3
 
 10
 
8
 
cell equivalent/ml in lysis buffer, and used as the membrane prep-
aration. Proteins from the samples were then separated by SDS-
PAGE as described in the above section.
 
Kinase Assays.
 
Kinase immune complexes from 2 
 
3 
 
10
 
7
 
 hy-
bridomas were incubated with 5 
 
m
 
Ci of adenosine triphosphate
([
 
g
 
-
 
32
 
P]ATP; Amersham Pharmacia Biotech) and the exogenous
kinase substrate enolase (Roche Biochemicals) in kinase buffer
(Hepes 20 mM, pH 7.4, 100 mM NaCl, 10 mM MgCl
 
2
 
, 10 mM
MnCl
 
2
 
, 50 mM NaF, and 1 
 
m
 
M ATP) for 2 or 10 min at 30
 
8
 
C.
Reactions were stopped by adding ice-cold reducing buffer. Im-
mune complexes were then separated by SDS-PAGE and ex-
posed to x-ray film (Eastman Kodak Co.). One fourth of the im-
munoprecipitates were subjected to Western blotting with the
indicated Abs.
 
TCR Downregulation.
 
Control and DEX-treated T cell hy-
bridomas were incubated for 1 h on flat-bottomed 96-well tissue
culture plates precoated with 10 
 
m
 
g/ml purified anti–TCR-
 
b
 
 in
PBS solution. CD3
 
e
 
 expression was assayed by flow cytometry
(FACSort™; Becton Dickinson) using FITC-coupled 145-2C11
(produced in our laboratory using standard techniques).
 
Glycolipid-enriched Membrane Microdomain Isolation.
 
Purifica-
tion of 
 
g
 
lycolipid-enriched membrane microdomains (GEMs)
was performed as described (29, 30). 10
 
8
 
/ml T cell hybridomas
were lysed on ice in 1 ml MNE buffer (morpholinoethane sul-
fonic acid [MES] 50 mM, pH 6.5, 150 mM NaCl, 5 mM EDTA)
 
containing 1% Triton X-100 (wt/vol), 1 mM Na
 
3
 
VO
 
4
 
, 1 mM
PMSF, and 1 mM NaF. Lysates were gently sonicated (five bursts
of 5 s at 5 W) and cleared at 5,000 rpm for 10 min at 4
 
8
 
C. 1 ml
supernatant was mixed with an equivalent volume of 80% sucrose
made with MNE buffer and transferred to a 5-ml ultracentrifuge
tube. This solution was carefully overlaid with 2 ml of 35% su-
crose followed by 1 ml of 5% sucrose (both prepared in MNE
buffer) and the tubes were placed in a cooled AH650 Sorvall ro-
tor. The gradients were then ultracentrifuged at 39,000 rpm for
16 h at 4
 
8
 
C. The GEM-containing fraction was obtained by col-
lecting the 5–35% sucrose interface, and the non-GEMs and cy-
tosolic fractions were harvested at the bottom of the gradient.
Fractions were then subjected to SDS-PAGE under reducing
conditions except for CD90 and CD45, which required nonre-
ducing conditions for adequate detection. Blots were revealed
using the appropriate primary and HRP secondary reagents and
developed by chemiluminescence. GM1 gangliosides were visual-
ized using HRP-coupled cholera toxin B subunit (Calbiochem).
GEM fractions were concentrated as described (31) and phos-
phoproteins were detected by Western blot analysis.
 
Results
 
DEX Inhibits TCR-proximal Tyrosine Phosphorylations.
 
GCs inhibit T cell–dependent immunity by blocking both
cytokine production and cell proliferation (22).
 
 
 
The
3B4.15 murine T cell hybridoma (26) was used in this
study as a model cell line to gain insight into the mecha-
nisms by which GCs antagonize signals delivered via the
TCR, as DEX inhibits TCR-induced IL-2 synthesis in this
cell line (Fig. 1 A), without affecting cell viability (as as-
sessed by
 
 
 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide [MTT] colorimetric assay; data not
shown). 3B4.15 cells were incubated overnight in DEX or
solvent (ethanol)-supplemented media and an equivalent
number of cells were stimulated with an anti-CD3
 
e
 
 mAb
(clone 7D6) at 37
 
8
 
C for 90 s. Whole cell lysates from
control and Ab-stimulated cells were submitted to immu-
noprecipitation using anti-CD3
 
e
 
–coupled agarose beads
(clone 145-2C11) and analyzed for protein tyrosine phos-
phorylation by immunoblotting (Fig. 1 B). Stimulation of
control cells led to the tyrosine phosphorylation of several
CD3
 
e
 
-associated substrates, including both a p23 and a p21
form of phospho-
 
z
 
, a TCR-associated phosphoprotein of
28–29 kD probably related to the phosphorylated form of
the CD3
 
e 
 
subunit, and a molecule of 70 kD that was iden-
tified as ZAP70 by immunoblotting (Fig. 1 B). The inten-
sity of some of these bands was reduced in extracts from
mAb-stimulated DEX-treated cells, suggesting that DEX
affected the early steps of TCR signaling in this cell line.
TCR stimulation appeared to be qualitatively affected by
GCs, as ZAP70, phospho-CD3
 
e
 
, and the high molecular
weight form of phospho-
 
z 
 
(p23) appeared to be selectively
hypophosphorylated in DEX-treated cells compared with
the p21 form of phospho-
 
z
 
 (Fig. 1 B). The preferential in-
hibition of the p23 high molecular weight form of phos-
pho-
 
z
 
 over the p21 isoform by DEX was further confirmed
by scan densitometry analysis of multiple independent ex-
periments (Fig. 1 C). Although DEX inhibited the tyrosine 
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phosphorylation of ZAP70 in T cell hybrids, it did not af-
fect its ability to associate with the TCR complex upon
CD3 triggering (Fig. 1 B). Accordingly, immunoprecipita-
tion studies using anti-ZAP70 Abs revealed that only un-
phosphorylated forms of ZAP70 were found to associate
with the TCR complex (Fig. 1 D). Of note, the integral
membrane adaptor molecule LAT is phosphorylated at
multiple tyrosine residues after TCR activation, creating
docking sites for numerous signaling molecules, including
PLC
 
g
 
1, Gads, and Grb2 (32–34). As LAT represents a
likely substrate for ZAP70, we investigated the effect of
GCs on its phosphorylation status. As shown in Fig. 1 E,
DEX was found to downregulate LAT tyrosine phosphor-
ylation induced upon TCR triggering, without affecting
LAT protein expression.
Steroid hormones may affect cell function through both
classical “genomic” effects (requiring binding to intracellu-
lar receptors and novel protein synthesis) and “nonge-
nomic” rapid (within minutes) effects mediated through
binding to putative membrane receptors (35). To investi-
gate the mechanism by which DEX affects the early wave
of intracellular tyrosine phosphorylation, T cell hybrids
were incubated in DEX-supplemented media and the ki-
netics and the sensitivity to an intracellular GC receptor
antagonist and to a protein synthesis inhibitor were ana-
lyzed. As shown in Fig. 2 (and keeping with our own pre-
vious observations, reference 26), the inhibitory effects of
DEX on LAT phosphorylation were characterized by de-
layed onset (
 
.
 
6 h) and required both binding to the GCs
receptor and de novo protein synthesis. Accordingly, DEX
did not inhibit TCR signal transduction in the Jurkat GC
receptor–negative cell line (data not shown).
To establish whether DEX could inhibit signal transduc-
tion in murine thymic cells, thymocytes from adult Balb/c
mice were treated in vitro with doses of DEX that did not
significantly affect cell viability or cell surface TCR expres-
sion (data not shown) and were stimulated by anti-CD3
mAbs as described previously. Whole cell extracts were
submitted to immunoprecipitation using anti-CD3
 
e
 
–cou-
pled agarose beads and the phosphorylation status of CD3-
associated chains was determined by immunoblotting. In
agreement with published reports (36, 37), the CD3
 
z 
 
chain
was constitutively phosphorylated in thymocytes, migrating
as a single p21 molecular species (Fig. 3 A). TCR stimula-
tion led to the appearance of the p23 phospho-
 
z
 
 isoform,
the p29 phospho-CD3
 
e
 
 chain, and the p70 ZAP70 phos-
phoband (see also Fig. 3 B). In keeping with studies per-
formed on a monoclonal cell line, treatment with low
Figure 1. DEX causes partial signaling in anti-CD3–
stimulated T cell hybridoma cells. (A) T cell hybrids
(3 3 104 cells/well) were stimulated by graded doses of
plastic-adsorbed anti-CD3e mAbs in control or 1 mM
DEX-supplemented media. Supernatants were col-
lected after overnight culture and IL-2 content was de-
termined using a standard ELISA. Results are expressed
as the mean 6 SD of triplicate determinations. TCR
signaling studies were performed as follows: T cell hy-
bridomas (2 3 107 cells/lane) were cultured for 16 h
with 1 mM DEX or solvent (ethanol). An equivalent
number of cells were left untreated or stimulated by
TCR cross-linking for 2 min and lysed in Brij97 lysis
buffer. (B) Lysates were immunoprecipitated (IP) with
Sepharose beads coupled to anti-CD3e or anti-CD3z
mAbs as indicated, resolved by SDS-PAGE, and immu-
noblotted (IB) with antiphosphotyrosine mAbs. The
blot was subsequently stripped and reprobed with an
mAb against CD3z and a ZAP70-specific rabbit antise-
rum. (C) The intensity of phospho-z isoforms resolved
by SDS-PAGE from nine independent experiments
was quantitated by densitometric analysis. Results are
expressed as percent inhibition of the relative intensity
of bands in DEX- versus control-treated cells (mean 6
SD). (D and E) Lysates were immunoprecipitated with
rabbit antisera raised against ZAP70 and LAT. Immu-
noprecipitates were resolved by SDS-PAGE and im-
munoblotted with antiphosphotyrosine mAbs. Stripped
membranes were reprobed with antisera raised against
ZAP70 and LAT (bottom). Similar results were ob-
tained in three independent experiments. D, DEX.807 Van Laethem et al.
doses (in the nanomolar range) of DEX inhibited the early
phosphorylating events secondary to TCR engagement, as
shown by reduced intensity of multiple phosphotyrosine-
containing bands, including p70 (ZAP70), p29 (CD3e),
and the p21 and p23 isoforms of CD3z. Reduction in the
intensity of phospho-z was not related to a diminished ex-
pression of z, as revealed by immunoblotting with an anti-z
chain mAb.
To further investigate the effect of DEX on developing
thymocytes, we used an in vitro model in which all T lin-
eage cells expressed a single defined TCR. Because of the
lack of MHC class I expression, thymocytes from F5 b2m2/2
Rag12/2 mice represent a homogeneous population of
immature CD41CD81 cells (9). These cells were incubated
overnight in the presence of control or DEX-supple-
mented media, washed, and exposed to graded doses of ag-
onist (NP68) or irrelevant (GAG) peptides presented by a
thymic epithelial cell line in the absence of GCs. The phos-
phorylation state of TCR-associated substrates was assessed
by phosphotyrosine-specific immunoblotting of anti-CD3e
immunoprecipitates. As shown in Fig. 3 B, ligation of the
F5 TCR on double positive thymocytes with NP68 re-
sulted in the phosphorylation of several substrates, includ-
ing ZAP70, CD3e, and the p23 isoform of the z chain.
The unrelated GAG peptide inefficiently stimulated the
thymocytes in this assay (reference 9, and data not shown),
inducing detectable p23 only when added at high concen-
trations (10 mM, Fig. 3 B; data not shown). Consistent
with previous experiments (Figs. 1 B and 3 A), DEX atten-
uated TCR signaling, as judged by decreased phosphoryla-
tion of several CD3-associated substrates, including CD3e
itself, ZAP70, and z. DEX also inhibited the constitutive
phosphorylation of the z chain, as shown by reduced inten-
Figure 2. Inhibition of TCR signaling by DEX requires binding to the
GC receptor and de novo protein synthesis. (A) T cell hybridomas were
incubated with media or 1 mM DEX for the indicated times before stim-
ulation by anti-CD3 mAbs. T cell hybridomas were preincubated for 2 h
in the presence of (B) the GC receptor antagonist RU486 (1 mM RU) or
(C) the protein synthesis inhibitor cycloheximide (0.25 mg/ml CHX) be-
fore addition of 0.1 mM DEX. The signaling properties of these cells
were analyzed after a 16-h incubation period as described in the legend
for Fig. 1. The results are representative of three independent experi-
ments. D, DEX. IP, immunoprecipitation.
Figure 3. DEX inhibits the early steps of TCR signaling in thy-
mocytes. (A) Balb/c thymocytes were incubated for 16 h in the indicated
concentrations of DEX or solvent (ethanol). Cultured thymocytes were
left untreated or stimulated by anti-CD3 mAbs at 378C for 2 min and
lysed in Brij97 lysis buffer. Cell lysates (2 3 107 cells/lane) were immu-
noprecipitated (IP) with an anti-CD3e mAb directly coupled to beads.
The immunoprecipitates were resolved by SDS-PAGE and immunoblot-
ted (IB) with antiphosphotyrosine mAbs. The amount of protein was
compared by reblotting the membrane with anti-CD3z mAbs (bottom).
(B) F5 b2m2/2Rag12/2 thymocytes were cultured overnight in 1 nM
DEX or solvent (ethanol) and left untreated or stimulated with the indi-
cated doses of agonist (NP68) or irrelevant (GAG) peptides presented by
YO1 thymic epithelial cells. Cell lysates (4 3 107 cells/lane) were immu-
noprecipitated with anti-CD3e mAbs and the immunoprecipitates were
resolved by SDS-PAGE and immunoblotted with antiphosphotyrosine
mAbs. Membranes were then stripped and blotted with anti-CD3z mAbs
(bottom). Similar results were obtained in three independent experi-
ments. D, DEX. 808 Dexamethasone Inhibits TCR Signaling
sity of the p21 band. A similar decrease in the z chain p21
and p23 isoforms was also observed in anti-ZAP70 immu-
noprecipitates from DEX-treated, NP68-stimulated thy-
mocytes (data not shown).
Collectively, these data demonstrate that DEX affects an
early step of the TCR signaling cascade, resulting in de-
creased phosphorylation of several substrates known to play
a key role in the recruitment and/or activation of down-
stream effectors regulating gene transcription.
DEX Inhibits TCR Downregulation. TCR-mediated ac-
tivation of T lymphocytes results in rapid and long-lasting
downregulation of cell surface–exposed TCR structures
(38). This phenomenon has been shown to be positively
controlled by the src kinase p56lck (39). To further charac-
terize the effect of DEX on the early steps of the TCR sig-
naling cascade, we analyzed the TCR cell surface expres-
sion of T cell hybrids stimulated by a short exposure to
plastic-adsorbed anti-TCR mAbs. In keeping with the idea
that GCs inhibit an early step of TCR signaling, DEX
treatment inhibited the early downregulation of the TCR
complex induced upon Ab-mediated activation (Fig. 4).
DEX Does Not Inhibit the Expression or the Enzymatic Ac-
tivity of the Tyrosine Kinases p56lck and p59fyn. Genetic
and mutational analyses have demonstrated that tyrosine ki-
nases of the src family are responsible for the early wave of
intracellular phosphorylations initiated upon TCR trigger-
ing and for the subsequent TCR downmodulation (39–
41). Therefore, we wished to assess whether GC treatment
affected the protein level and/or tyrosine kinase activity of
the p56lck and p59fyn protein tyrosine kinases (PTKs). Im-
munoblotting experiments performed on whole cell ex-
tracts from the 3B4 cell line indicated that the expression
levels of these kinases were not affected by DEX exposure
(data not shown). To verify whether GCs affected protein
intracellular partition, cytosolic and membrane extracts
were prepared after overnight incubation of T cell hybrids
in ethanol or DEX-supplemented media. The purification
procedure was assessed by probing the blots with Abs
to membrane-bound (CD90) and cytoplasmic proteins
(PLCg1, ZAP70). As shown in Fig. 5 A, DEX did not af-
fect the intracellular localization of the p56lck and p59fyn
Figure 4. DEX inhibits activation-induced TCR downregulation.
Control and DEX-treated (1 mM) T cell hybridomas were stimulated by
plastic-coated anti–TCR-b mAbs (H57-957) for 1 h at 378C in 96-well
culture plates. Cells were then recovered and analyzed for CD3e expres-
sion by flow cytometry.
Figure 5. DEX does not affect the cellular distribu-
tion or the kinase activity of p56Lck and p59Fyn. (A)
Cytosolic and membrane proteins from unstimulated
control and DEX-treated hybridomas (4 3 107 cells/
condition) were separated as described in Materials
and Methods. Equivalent amounts of proteins from
both fractions were separated by SDS-PAGE and
blotted with the indicated Abs. Lysates from DEX-
treated T cell hybridomas (2 3 107 cells/lane) were
immunoprecipitated (IP) with (B) anti-p56Lck mAbs,
(C) anti-CD4 mAbs, or (D) a rabbit serum raised
against p59Fyn, and the resulting immune complexes
were incubated for the indicated times at 308C with
[g-32P]ATP and the exogenous substrate enolase, sep-
arated by SDS-PAGE, and exposed to x-ray film for
24 h. One fourth of the immune complexes were an-
alyzed by immunoblotting with the relevant anti-
kinase Ab (bottom). The results are representative of
three independent experiments. D, DEX.809 Van Laethem et al.
PTKs. The in vitro enzymatic activity of the p56lck and
the p59fyn PTKs was not significantly affected by over-
night incubation in DEX-supplemented media, as assayed
on the exogenous substrate enolase (Fig. 5, B and D). The
faint bands migrating in the 56–60-kD range comigrate
with bands revealed by antikinase Abs in Western blots
performed in parallel gels and probably represent the auto-
phosphorylated forms of these kinases (data not shown).
DEX did not affect the protein levels and kinase activity of
the CD4-associated forms of p56lck, as shown by immuno-
precipitation studies performed using Abs to CD4 (Fig. 5
C). Collectively, these data indicated that DEX exposure
did not affect the expression level or the in vitro enzymatic
activity of the p56lck and p59fyn kinases.
DEX Affects the Membrane Compartmentalization of Key
Transducing Molecules. Recently, the important role of
GEMs or detergent-insoluble lipid rafts in cell signaling has
been recognized (42, 43). These GEMs are enriched in gly-
cosyl phosphatidylinositol (GPI)-linked glycoproteins and
in other lipid-modified proteins such as tyrosine kinases of
the src family, monomeric and heterotrimeric G proteins,
G-coupled protein receptors, and the adaptor protein LAT
(30, 42–45). The confinement of signaling molecules to
membrane subdomains suggests that these compartments
function as platforms for the formation of multicomponent
transduction complexes (46, 47). Accordingly, studies per-
formed on T lymphocytes have shown that raft integrity is
required for effective TCR signal transduction (44, 48–50).
To determine the effects of GCs on GEM composition, T
cell hybrids were lysed in a cold buffer containing a non-
ionic detergent, and detergent-resistant membrane constit-
uents were fractionated by ultracentrifugation in a sucrose
gradient (51). The GEMs and the detergent-soluble frac-
tion were analyzed by Western blot analysis using Abs and
reagents to membrane components and signaling mole-
cules. As expected, CD45, a transmembrane protein
known to be excluded from the GEMs (52), and PLCg1, a
cytoplasmic protein, were only detected in the soluble frac-
tion (Fig. 6 A). DEX did not overtly affect the plasma
membrane microdomains, as GEMs enriched for both the
GPI-linked CD90/Thy-1 protein and the ganglioside
GM1 could be isolated from both control and DEX-
treated cells. However, GCs were found to selectively af-
fect the submembrane localization of several key signaling
molecules, since GEMs purified from DEX-treated cells
displayed a marked decrease in the amount of p56lck,
p59fyn, and LAT, as determined by Western blotting.
DEX treatment did not affect the cellular expression level
of these proteins, as judged by Western blots performed on
whole cell extracts (data not shown), membrane fractions
(Fig. 5 A), or specific immunoprecipitates (Fig. 1 E and
Fig. 5, B and D). Noteworthy, since proteins in GEMs
Figure 6. DEX affects membrane signaling complexes.
(A) GCs affect protein raft composition. Control and
DEX-treated T cell hybridomas (108 cells/condition) were
solubilized in 1% Triton X-100 MES lysis buffer, gently
sonicated, and the subsequent lysates were ultracentrifuged
in a sucrose gradient as described in Materials and Meth-
ods. Undiluted GEMs and cytoplasmic fractions (1:4 dilu-
tion to avoid abnormal migration) from control and DEX-
treated unstimulated cells were separated by SDS-PAGE
and immunoblotted with Abs to membrane-associated
(CD90, CD45, CD3z, p59Fyn, p56Lck, LAT) and cyto-
plasmic (PLCg1) proteins. The ganglioside GM1 was de-
tected using HRP-coupled cholera toxin B subunit. (B)
Reduced phospho-LAT in the GEM fraction of DEX-
treated cells. Control and DEX-treated hybridomas were
left untreated or stimulated by CD3 cross-linking for 2 min
and lysed in 1% Triton X-100 MES buffer. Lysates were
ultracentrifuged as described previously and GEM fractions
were concentrated as described in Materials and Methods,
separated by SDS-PAGE, and immunoblotted (IB) with
antiphosphotyrosine mAbs. Similar results were obtained
in five independent experiments. (C) Coimmunoprecipita-
tion of LAT with CD90 requires membrane cholesterol. T
cell hybridomas (107 cells/condition) were pretreated with
10 mM methyl-b-cyclodextrin (MCD) for 30 min at 378C
or with 0.2% saponin for 10 min at 48C in PBS before lysis
in 1% Triton X-100 MES buffer. After sonication, lysates
were subjected to immunoprecipitation (IP) with anti-
CD90 (clone HO-13.4)–coupled Sepharose beads. Immu-
noprecipitates were resolved by SDS-PAGE and immuno-
blotted with the indicated Abs. (D) DEX affects signaling
complexes. T cell hybridomas were incubated in control
and 1 mM DEX-supplemented media before lysis and im-
munoprecipitation with anti-CD90 mAbs. Proteins in total
extracts (2 3 105 cells/lane) or anti-CD90 immunoprecip-
itates (from 107 cells/lane) were revealed by immunoblot-
ting with the indicated Abs. D, DEX.810 Dexamethasone Inhibits TCR Signaling
only represent a minor fraction of the total cellular protein
content (z1–2%), loss of a given protein from the GEMs
does not always lead to a detectable increase in the deter-
gent-soluble fraction. Consistent with previous publica-
tions (44, 45), TCR activation led to the tyrosine phos-
phorylation of GEM-associated proteins such as LAT (Fig.
6 B). In keeping with observations performed on immuno-
precipitates, DEX inhibited the amount of phospho-LAT
in the GEM fraction (Fig. 6 B), possibly as a consequence
of altered membrane compartmentalization and/or reduced
access to the appropriate kinase.
The existence of signaling complexes at the cell mem-
brane can also be demonstrated by coimmunoprecipitation
studies. In particular, the GPI-anchored Thy-1 molecule is
known to associate with elements of the intracellular sig-
naling machinery (53, 54). Noteworthy, these molecular
associations require membrane cholesterol, suggesting that
such linkages may occur by virtue of colocalization to
membrane subdomains (54). To further document the ef-
fects of GCs on these signaling complexes, postnuclear su-
pernatants obtained after extraction of 3B4 cells in 1% Tri-
ton X-100 were immunoprecipitated using an anti–Thy-1
mAb and analyzed by immunoprecipitation. In keeping
with previous observations, signaling proteins were found
to coimmunoprecipitate with Thy-1 under these experi-
mental conditions, whereas transmembrane (CD3z) and
cytoplasmic (PLCg1) proteins were excluded from these
complexes (Fig. 6 D). Noteworthy, cholesterol depletion
by methyl-b-cyclodextrin or saponin prevented these mo-
lecular associations (including Thy-1/LAT coimmunopre-
cipitation, shown as an example in Fig. 6 C), suggesting
that coimmunoprecipitation required membrane subdo-
main integrity. In agreement with our previous observa-
tions, anti–Thy-1 immunoprecipitates from DEX-treated
cells displayed reduced amounts of p59fyn and LAT pro-
teins, suggesting that GCs affected the association of several
signaling molecules with membrane microdomains en-
riched in GPI-anchored proteins and cholesterol. Collec-
tively, the observations reported in Fig. 6 strongly suggest
that DEX inhibits the early steps of TCR signaling by af-
fecting the submembrane localization of important signal-
ing molecules.
Discussion
GCs are potent immunosuppressive agents able to inhibit
the expression of several proteins involved in inflammatory
immune responses. In particular, their ability to inhibit T
cell responses is thought to be related to the modulation of
gene expression induced upon TCR triggering. Negative
regulation of gene transcription in activated T lymphocytes
can occur directly by competition for DNA binding sites in
the promoter region of several cytokine-encoding genes,
or indirectly, by sequestration/binding to transcription fac-
tors such as activator protein-1, nuclear factor kB, cAMP
response element–binding protein (CREB), octamer bind-
ing factor 1, and signal transducer and activator of tran-
scription 5 (55, and references therein). Previously, we
have shown that in addition to their effect on gene tran-
scription, GCs can inhibit an early step of TCR-initiated
signal transduction, causing impaired calcium flux in acti-
vated murine T lymphocytes and T cell hybrids (26). Re-
cently, numerous reports have underlined the importance
of the early signaling events in determining cell fate deci-
sion in the immune system, leading us to further explore
the mechanisms by which GCs antagonize TCR-issued
signals.
In this study we provide evidence that DEX, a synthetic
GC analogue, affects the response of T cells to a given
TCR ligand by interfering with a membrane-proximal
phosphorylative event, thus identifying a novel mechanism
by which GCs exert their antiinflammatory properties.
TCR stimulation of DEX-treated cells led to a defective
phosphorylation of CD3-associated substrates, including
the  z chain. In keeping with numerous observations sug-
gesting a key role for z in transducing activation signals (3,
56), cells expressing reduced amounts of phospho-z also
displayed reduced phosphorylation of other molecules
known to play a major role in relaying activation signals to
downstream effectors, including the ZAP70 kinase and the
adaptor molecule LAT. The pattern of phosphorylative
events evoked in DEX-treated cells suggests that GCs may
affect T responses in a partial agonist fashion, as TCR oc-
cupancy in a DEX-treated T cell hybridoma only evoked a
subset of the signaling events observed in control-stimu-
lated cells. In particular, the recruitment of ZAP70 to the
TCR complex and the accumulation of p21 phospho-z
were not or were only weakly affected by GCs in activated
cells, whereas other intracellular events (phosphorylation of
CD3z p23 form, ZAP70, LAT, PLCg1, and sustained cal-
cium influx; this study and reference 26) were inhibited.
Similarly, the profile of phosphorylative events observed in
DEX-treated thymocytes was reminiscent of the pattern of
phosphoproteins induced by altered peptide ligands in de-
veloping thymocytes. Indeed, in the F5 TCR transgenic
model, peptides known to favor positive selection in vitro
were shown to reduce z chain phosphorylations in a more
quantitative that qualitative fashion (9). Previous studies
have suggested that the ordered phosphorylation of CD3z
establishes the threshold for T cell activation (56). These
studies identified the CD3-associated ITAM modules as
critical signaling thresholds detectors, able to integrate
graded signals such as TCR signal strength (15–17), co-
stimulation (57–59), and CTLA4 engagement (60) into all-
or-none developmental decisions. This study demonstrates
that CD3z is also sensitive to the hormonal environment,
suggesting an important and complex role for CD3-associ-
ated ITAMs in relaying external cues to the interior of the
cell.
The mechanism by which DEX affects the early steps of
TCR signaling was further studied using a T cell hybrid
known to resist the proapoptotic effects of GCs (26). In this
cell line, DEX did not affect the expression or the in vitro
PTK activity of p56lck and p59fyn, which have been
shown to positively regulate the early steps of signaling
events (such as phosphorylation of CD3z and TCR down-811 Van Laethem et al.
modulation) inhibited by GCs. This observation suggests
that PTK activity is not the primary target of DEX, arguing
against a role for Csk (a tyrosine kinase known to inhibit
the enzymatic activity of p56lck; reference 61), CD45, or
src homology 2 domain–bearing protein tyrosine phos-
phatase 1 (SHP-1) (hematopoietic tyrosine phosphatases
able to downregulate Lck kinase activity; references
62, 63).
Analysis of membrane subdomains revealed a possible
mechanism by which DEX may modulate TCR signaling.
Recently it has been suggested that src PTKs and other im-
portant signaling molecules including LAT are confined
into specific detergent-resistant plasma membrane domains
(GEMs) enriched in sphingolipids and GPI-anchored pro-
teins (30, 43, 44). The fact that components of the TCR–
CD3 complex are recruited into the GEMs upon stimula-
tion and phosphorylated on tyrosine residues within this
compartment argues for an important role of these mem-
brane domains in signal transduction (46). Accordingly,
numerous experiments indicate that disruption of GEMs
(and the consequent dispersion of their content into the
detergent-soluble membrane fraction) inhibits TCR signal
transduction (43, 44, 47, 48). The present report suggests
that DEX affects the submembrane compartmentalization
of several molecules associated with the inner (cytoplasmic)
lipid layer of the GEMs, including the src PTKs, p56lck
and p59fyn. Based on the current literature, displacement
of Src family kinases and LAT from the GEMs might be
because of modification of the GEM lipid content (such as
lower cholesterol content and/or the phospholipid compo-
sition; references 47–49) or by altered protein acylation.
Indeed, studies using Lck and LAT mutant proteins lacking
acylation sites have shown that these proteins are excluded
from the GEMs in transfected T cells and are unable to
transduce signals issued from the TCR (30, 64, 65). How-
ever, note that an Lck mutant that cannot be palmitoylated
is unable to associate with membranes (65), whereas DEX
failed to affect stable membrane interaction of Lck (Fig. 5
A). Moreover, no effect of DEX on membrane-associated
cholesterol was evidenced by filipin staining (unpublished
observations). In any event, the results reported in this
study are consistent with the view that disruption of GEMs
may be the primary cause of partial signaling in DEX-
treated T cells. Dispersion of signaling molecules such as
Lck or Fyn in the soluble membrane fraction may affect
their enzymatic activity, as it has been recently recognized
that these kinases exhibit optimal activity only when associ-
ated with cholesterol-enriched domains (66). Moreover,
altered membrane localization may impede an adequate
juxtaposition of PTKs with their substrate upon TCR
stimulation or cause their sequestration in ineffective sig-
naling complexes, resulting in a novel pattern of phosphor-
ylating events and altered biological response. Of interest,
it has been recently demonstrated that inhibition of CD4
association with the Ag–MHC-engaged TCR leads to par-
tial signaling (predominant accumulation of the p21 iso-
form of phospho-z) in response to an agonist (67). Collec-
tively, these data strongly suggest that partial signaling may
be a consequence of ineffective clustering of TCR subunits
with the relevant membrane-associated src PTKs. The
analysis of phospho-z p21 isoform levels in unstimulated
cells is in agreement with this hypothesis. Reduced levels
of p21 in these cells (Fig. 1 B) appear to be the conse-
quence of altered membrane localization of PTKs (Fig. 6
A), as both CD3z submembrane compartmentalization
(Fig. 6 A) and PTK enzymatic activity (Fig. 5) were unaf-
fected by DEX treatment.
The interest in the phenomenon reported here lies in its
possible in vivo relevance. Thymic selection, a process
whereby autoreactive thymocytes are induced to die (nega-
tive selection) while thymocytes displaying self-MHC–
restricted potential are allowed to differentiate into mature
T cells (positive selection), is thought to depend on subtle
differences in the signals issued by the TCR in response to
self-peptide–MHC complexes expressed in the thymus (1,
68, 69). Recently, it has been demonstrated that the thymic
epithelium and possibly thymocytes themselves produce
steroids, suggesting a potential role of GCs in the control of
T cell development and repertoire development (23, 70).
Accordingly, downregulation of GC receptors on thy-
mocytes and/or pharmacological inhibition of GC synthe-
sis have been shown to affect thymic differentiation in vivo
(71, 72). These authors have proposed that GCs produced
in the thymus antagonize TCR signals, thus shifting the
positive selection window towards higher TCR avidities
for self-Ag–MHC complexes. The work presented here
provides a sound basis for explaining these observations.
We propose that GCs may affect thymocyte development
by modifying the early signals issued by the TCR, convert-
ing an agonist signal (causing negative selection) into a pos-
itively selecting, partial agonist–like signal. Similarly, GCs
may cause cell death by the neglect of cells expressing
TCRs with very low self-reactivity. Therefore, it is tempt-
ing to speculate that by lowering TCR sensitivity, GCs
may shift the range of positively selected TCRs towards a
higher self-reactivity, possibly ensuring that T cells surviv-
ing positive selection display a sufficient reactivity to self-
MHC in the periphery. Noteworthy, this hypothesis pos-
tulates that lack of thymic GC receptor expression would
lead to subtle changes in repertoire selection, with no ma-
jor alteration in overall thymic cellularity. In keeping with
this hypothesis, lack of GC responsiveness led to the spe-
cific loss of T cells bearing a TCR specific for a given Ag
(73), with no major impact on thymic cell numbers and
phenotype (74).
Signal strength has also been proposed to regulate the
development of helper subsets in the periphery. Numerous
studies have suggested that “weak” and/or partial signaling
in mature lymphocytes favors Th2 cell development. Prim-
ing of naive T cells with optimal doses of an agonist pep-
tide will induce Th1 development, whereas very low doses
of an agonist peptide or stimulation by a low-avidity al-
tered peptide ligand will favor Th2 differentiation (11, 75).
GCs in vivo and in vitro have been shown to favor Th2
cell differentiation in response to Ag (24, 76, 77), suggest-
ing again that by reducing TCR signal strength, GCs may812 Dexamethasone Inhibits TCR Signaling
affect cell fate decisions in the periphery. Noteworthy, we
and others have proposed previously that GCs may favor
Th2 development by affecting both survival of dendritic
cells and IL-12 production (78–80). These observations
suggest that by affecting both APC function and TCR sig-
naling, endogenous GCs produced during acute infection
may favor the development of Th2-like cells with antiin-
flammatory properties.
In conclusion, our study illustrates a novel aspect of the
signaling flexibility of the TCR, revealing that in addition
to avidity for Ag–MHC and costimulation, environmental
factors such as GC hormones determine the nature of intra-
cellular signals induced by the TCR. Further studies are re-
quired to better understand how all these influences are
translated in vivo into distinct functional responses.
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